Breaking News Instant updates and real-time market news.

PCRX

Pacira

$29.50

0.65 (2.25%)

14:40
04/06/18
04/06
14:40
04/06/18
14:40

Call buyers in Pacira Pharmaceuticals as shares see relative strength

Call buyers in Pacira Pharmaceuticals as shares see relative strength. The stock up $3 to $32.50 on positive FDA news and Apr 32.5 calls trade at prices ranging from 70c to $3 per contract. Nearly 5K changed hands against 481 open interest and the market is $1.40 to 2.45.

  • 06

    Apr

  • 16

    Apr

PCRX Pacira
$29.50

0.65 (2.25%)

03/19/18
JEFF
03/19/18
NO CHANGE
Target $30
JEFF
Buy
Heron pain drug 'hits a home run' in Phase III studies, says Jefferies
Jefferies analyst Biren Amin says Heron Therapeutics's (HRTX) HTX-011 "hits a home run" by meeting all primary and key secondary endpoints this morning from Phase III trials in bunionectomy and hernia repair. Safety looked clean in both studies, and HTX-011 produced durable pain reduction up to 72 hours and significant opioid sparing effect and differentiates from generic bupivacaine, Amin tells investors in a research note. The analyst believes HTX-011 should receive a superiority claim versus generic bupivacaine in its label for both bunionectomy and hernia surgery. Amin notes that Pacira's (PCRX) Exparel does not have this claim in its label. He assumes peak sales of $545M for HTX-011 and keeps a Buy rating on Heron with $30 price target.
03/20/18
GHSC
03/20/18
NO CHANGE
Target $42
GHSC
Buy
Pacira price target lowered to $42 after Heron data at Seaport Global
Seaport Global analyst Corey Davis noted that Heron Therapeutics (HRTX) reported positive results from its two Phase 3 studies of HTX-011 for postoperative pain in bunionectomy and herniorrhaphy. While Heron's HTX-011 data suggest some competition in 2020 for Pacira's (PCRX) Exparel, Davis said dose and volume "present problems" and that Heron "may run into a pricing problem" as well. He reiterates his Buy rating on Pacira shares, though he lowered his price target on the stock to $42 from $50, noting that he has formally removed nerve block revenue for Exparel entirely from his model after the negative FDA AdCom last month.
03/21/18
JEFF
03/21/18
NO CHANGE
Target $49
JEFF
Buy
Pacira shares could be positioned for rebound, says Jefferies
Jefferies analyst David Steinberg believes shares of Pacira Pharmaceuticals could be positioned for a rebound after Symphony Health data indicated Exparel posted "well above trend growth" in February. Sales were $24M, up 3.4% from last month and up 12.6% year-over-year, according to Symphony. The data have shown double digit year-over-years gains in four of the past five months, versus just one of nine months prior, Steinberg tells investors in a research note. He believes Pacira is attractively valued at current levels and keeps a Buy rating on the shares with a $49 price target.
04/06/18
WEDB
04/06/18
NO CHANGE
Target $72
WEDB
Outperform
Wedbush says FDA response for Pacira's EXPAREL in nerve block due
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.

TODAY'S FREE FLY STORIES

EWW

iShares MSCI Mexico

$49.18

-0.055 (-0.11%)

06:45
08/17/18
08/17
06:45
08/17/18
06:45
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$25.59

-0.01 (-0.04%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$21.16

(0.00%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

, EQGP

EQT GP

$22.25

0.2 (0.91%)

06:43
08/17/18
08/17
06:43
08/17/18
06:43
Recommendations
EQT Midstream Partners, EQT GP analyst commentary  »

EQT Midstream price…

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

EQGP

EQT GP

$22.25

0.2 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$49.85

0.61 (1.24%)

06:41
08/17/18
08/17
06:41
08/17/18
06:41
Recommendations
EQT Corporation analyst commentary  »

EQT Corporation price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$15.64

0.13 (0.84%)

06:37
08/17/18
08/17
06:37
08/17/18
06:37
Initiation
Cott Corp. initiated  »

Cott Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.03

-0.0172 (-36.44%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Periodicals
MoviePass puts additional restrictions on subscribers, NY Post says »

MoviePass chief Mitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFET

Safe-T

$0.00

(0.00%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Syndicate
Safe-T raises $7.335M in a registered direct offering »

Safe-T announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.83

0.44 (1.36%)

, FB

Facebook

$174.76

-4.78 (-2.66%)

06:33
08/17/18
08/17
06:33
08/17/18
06:33
Periodicals
Twitter CEO criticizes Facebook, YouTube for Alex Jones' removal, BI reports »

Twitter (TWTR) CEO Jack…

TWTR

Twitter

$32.83

0.44 (1.36%)

FB

Facebook

$174.76

-4.78 (-2.66%)

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 06

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

AZRE

Azure Power

$15.95

-0.405 (-2.48%)

06:30
08/17/18
08/17
06:30
08/17/18
06:30
Initiation
Azure Power initiated  »

Azure Power initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNHPF

Hon Hai Precision

$0.00

(0.00%)

, AAPL

Apple

$213.49

3.21 (1.53%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Periodicals
Foxconn to launch semiconductor plant in China's Pearl River Delta, WSJ says »

Foxconn Technology, …

HNHPF

Hon Hai Precision

$0.00

(0.00%)

AAPL

Apple

$213.49

3.21 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMC

Yum China

$35.33

0.29 (0.83%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Downgrade
Yum China rating change  »

Yum China downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LGND

Ligand

$239.84

-7.88 (-3.18%)

06:25
08/17/18
08/17
06:25
08/17/18
06:25
Initiation
Ligand initiated  »

Ligand initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

, GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

06:24
08/17/18
08/17
06:24
08/17/18
06:24
Periodicals
Google CEO responds to criticism over plan for search engine in China, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

BXG

Bluegreen Vacations

$20.39

-0.65 (-3.09%)

06:22
08/17/18
08/17
06:22
08/17/18
06:22
Downgrade
Bluegreen Vacations rating change  »

Bluegreen Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:21
08/17/18
08/17
06:21
08/17/18
06:21
Earnings
Deere reports Q3 EPS 2.78, consensus $2.75 »

Reports Q3 worldwide net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

WMT

Walmart

$98.63

8.39 (9.30%)

, COST

Costco

$223.20

1.55 (0.70%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Walmart, Costco, Target analyst commentary  »

Walmart price target…

WMT

Walmart

$98.63

8.39 (9.30%)

COST

Costco

$223.20

1.55 (0.70%)

TGT

Target

$82.07

1.38 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 04

    Oct

KORS

Michael Kors

$71.94

0.63 (0.88%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Michael Kors analyst commentary  »

Michael Kors price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

ENB

Enbridge

$34.89

-0.19 (-0.54%)

06:18
08/17/18
08/17
06:18
08/17/18
06:18
Upgrade
Enbridge rating change  »

Enbridge upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$53.58

1.24 (2.37%)

06:17
08/17/18
08/17
06:17
08/17/18
06:17
Recommendations
Dave & Buster's analyst commentary  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:16
08/17/18
08/17
06:16
08/17/18
06:16
Hot Stocks
Deere CEO says 'continue face cost pressures for raw materials and freight' »

"Deere's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

FB

Facebook

$174.76

-4.78 (-2.66%)

06:15
08/17/18
08/17
06:15
08/17/18
06:15
Periodicals
Facebook begins to crack down on opioid dealers, TechCrunch reports »

Facebook's internal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

TM

Toyota

$122.76

0.9 (0.74%)

06:14
08/17/18
08/17
06:14
08/17/18
06:14
Periodicals
Toyota to boost production capacity in China by 20%, Reuters says »

Toyota will add more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:13
08/17/18
08/17
06:13
08/17/18
06:13
Earnings
Deere sees FY18 equipment revenue up about 30%, consensus $33.78B »

Company equipment sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

SUI

Sun Communities

06:12
08/17/18
08/17
06:12
08/17/18
06:12
Downgrade
Sun Communities rating change  »

Sun Communities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.